Please provide your email address to receive an email when new articles are posted on . Researchers at Cleveland Clinic have initiated a first-of-its-kind study of a vaccine designed to ultimately ...
Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...
Opthea's Phase 3 COAST trial for wet AMD failed its primary endpoint, raising concerns about the company's financial stability. Opthea Limited announced that its global Phase 3 trial, COAST, ...
Matthew (he/him) is an Evergreen Editor at DualShockers. He has been in games media for two years. He has held various roles, such as staff writer, writing specialist, and editor. After graduating ...
Often referred to as forced negatives, this technique involves resisting the eccentric (lowering) phase of a lift under a load heavier than you can lift concentrically. Zach Even-Esh reflects on his ...
At first blush, recent Phase 3 trial results from the anti-amyloid antibodies gantenerumab and lecanemab seem to be a study in opposites, one negative and one positive. At the 15th Clinical Trials on ...
New research paper from 24-person research team from Berkeley, Georgia Tech, MIT, and other institutions. Find the open access Technical paper here. Published March 2022. The Georgia Tech news article ...
ARX788 is a next-generation, site-specific antibody-drug conjugate (ADC). Its mechanism of action involves a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), conjugated ...
Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback